![](images/null.gif) |
![](images/null.gif) |
![](images/null.gif) |
|
Long-term efficacy of bictegravir/emtricitabine/tenofovir alafenamide after switch from boosted protease inhibitor-based regimens including in those with preexisting resistance and viral blips
|
|
|
EACS 2021 Oct 27-30
K. Andreatta1, S. Chang1, M. Delaney1, M. Willkom1, R. Martin1, H. Graham1, H. Martin1, K.L. White1
1Gilead Sciences, Inc., Foster City, United States
![1030211](../images/103021/103021-4/1030211.gif)
![1030212](../images/103021/103021-4/1030212.gif)
![1030213](../images/103021/103021-4/1030213.gif)
![1030214](../images/103021/103021-4/1030214.gif)
![1030215](../images/103021/103021-4/1030215.gif)
![1030216](../images/103021/103021-4/1030216.gif)
![1030217](../images/103021/103021-4/1030217.gif)
![1030218](../images/103021/103021-4/1030218.gif)
![1030219](../images/103021/103021-4/1030219.gif)
![10302110](../images/103021/103021-4/10302110.gif)
|
|
|
![](images/null.gif) |
![](images/null.gif) |
|
|